Downregulation of Smad4 expression confers chemoresistance against imatinib mesylate to chronic myeloid leukemia K562 cells

References

• Hamad, A., et al., Emerging therapeutic strategies for targeting chronic myeloid leukemia stem cells. 2013.
   Google Scholar
• Stapnes C, Gjertsen B, Reikvam H, et al. Targeted therapy in acute myeloid leukaemia: current status and future directions. Expert Opinion on Investigational Drugs. 2009;18(4):433–455.
   Google Scholar
• Ito TJIJOH. Stem cell maintenance and disease progression in chronic myeloid leukemia. Int J Hematol. 2013;98(6):641–647.
   Google Scholar
• Cross N, Daley G, Green A, et al. BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features. Leukemia. 2008;22(11):1975–1989.
   Google Scholar
• Perrotti D, Jamieson C, Goldman J, et al. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest. 2010;120(7):2254–2264.
   Google Scholar
• El-Shami K, Smith BJL. Immunotherapy for myeloid leukemias: current status and future directions. Leukemia. 2008;22(9):1658–1664.
   Google Scholar
• Cea M, Cagnetta A, Nencioni A, et al. New insights into biology of chronic myeloid leukemia: implications in therapy. Curr Cancer Drug Targets. 2013;13(7):711–723.
   Google Scholar
• Hochhaus A, O'Brien A, Guilhot S, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23(6):1054–1061.
   Google Scholar
• Pophali PA, Patnaik MMJCJ. The role of new tyrosine kinase inhibitors in chronic myeloid leukemia. Cancer J. 2016;22(1):40.
   Google Scholar
• Massagué J. TGFβ signalling in context. Nat Rev Mol Cell Biol. 2012;13(10):616–630.
   PubMed Web of Science ®Google Scholar
• Malkoski SP, Wang X-J. Two sides of the story? Smad4 loss in pancreatic cancer versus head-and-neck cancer. FEBS Lett. 2012;586(14):1984–1992.
   PubMed Web of Science ®Google Scholar
• Haeger SM, Thompson JJ, Kalra S, et al. Smad4 loss promotes lung cancer formation but increases sensitivity to DNA topoisomerase inhibitors. Oncogene. 2016;35(5):577–586.
   PubMed Web of Science ®Google Scholar
• Liu J, Cho S-N, Akkanti B, et al. Erbb2 pathway activation upon Smad4 loss promotes lung tumor growth and metastasis. Cell Rep. 2015;10(9):1599–1613.
   PubMed Web of Science ®Google Scholar
• Tascilar M, et al. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2001;7(12):4115–4121.
   PubMed Web of Science ®Google Scholar
• Bornstein S, et al. Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation. J Clin Invest. 2009;119(11):3408–3419.
   PubMed Web of Science ®Google Scholar
• Izeradjene K, Combs C, Best M, et al. Krasg12d and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell. 2007;11(3):229–243.
   PubMed Web of Science ®Google Scholar
• Ding Z, Wu C-J, Chu GC, et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature. 2011;470(7333):269–273.
   PubMed Web of Science ®Google Scholar
• Li Q, Liu X, Zhao C. Smad4 gene silencing enhances the chemosensitivity of human lymphoma cells to Adriamycin via inhibition of the activation of transforming growth factor β signaling pathway. J Cell Biochem. 2019;120(9):15098–15105.
   PubMed Web of Science ®Google Scholar
• Zhang B, Zhang B, Chen X, et al. Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway. Br J Cancer. 2014;110(4):946–957.
   PubMed Web of Science ®Google Scholar
• Zhao M, Mishra L, Deng CX. The role of TGF-β/SMAD4 signaling in cancer. Int J Biol Sci. 2018;14(2):111–123.
   PubMed Web of Science ®Google Scholar
• Fang L, et al. LAMC1, upregulated by TGFβ in tumor cells, contributed to the formation of inflammatory cancer-associated fibroblasts via NF-kB/CXCL1/STAT3 in esophageal squamous cell carcinoma. 2021.
   Google Scholar
• Nishikawa R, et al. Tumor-suppressive microRNA-29s inhibit cancer cell migration and invasion via targeting LAMC1 in prostate cancer. Int J Oncol. 2014;45(1):401–410.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xi S, Chen J, et al. Overexpression of LAMC1 predicts poor prognosis and enhances tumor cell invasion and migration in hepatocellular carcinoma. J Cancer. 2017;8(15):2992.
   PubMed Web of Science ®Google Scholar
• Ye G, Qin Y, Wang S, et al. Lamc1 promotes the Warburg effect in hepatocellular carcinoma cells by regulating PKM2 expression through AKT pathway. Cancer Biol Ther. 2019;20(5):711–719.
   PubMed Web of Science ®Google Scholar
• Kunitomi H, Kobayashi Y, Wu R-C, et al. LAMC1 is a prognostic factor and a potential therapeutic target in endometrial cancer. J Gynecol Oncol. 2020;31(2):e11.
   PubMed Web of Science ®Google Scholar
• Liu J, Liu D, Yang Z, et al. High LAMC1 expression in glioma is associated with poor prognosis. Onco Targets Ther. 2019;12:4253.
   PubMed Web of Science ®Google Scholar
• Brachet-Botineau M, Deynoux M, Vallet N, et al. A novel inhibitor of STAT5 signaling overcomes chemotherapy resistance in myeloid leukemia cells. Cancers (Basel). 2019;11(12):2043.
   PubMed Web of Science ®Google Scholar
• Chalandon Y, Thomas X, Hayette S, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015;125(24):3711–3719.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Cortes J, Jabbour E, et al. Chronic myeloid leukemia. Mol Hematol. 2019: 71–86.
   PubMedGoogle Scholar
• Shokeen Y, et al. Association between altered expression and genetic variations of transforming growth factor β-Smad pathway with chronic myeloid leukemia. Int J Hematol Oncol Stem Cell Res. 2018;12(1):14–22.
   PubMedGoogle Scholar
• Cheng Y, Li Z, Xie J, et al. MiRNA-224-5p inhibits autophagy in breast cancer cells via targeting Smad4. Biochem Biophys Res Commun. 2018;506(4):793–798.
   PubMed Web of Science ®Google Scholar
• Wang F, Xia X, Yang C, et al. SMAD4 gene mutation renders pancreatic cancer resistance to radiotherapy through promotion of autophagy. Clin Cancer Res. 2018;24(13):3176–3185.
   PubMed Web of Science ®Google Scholar
• Xia X, Wu W, Huang C, et al. SMAD4 and its role in pancreatic cancer. Tumour Biol. 2015;36(1):111–119.
   PubMedGoogle Scholar
• Désert R, Mebarki S, Desille M, et al. “Fibrous nests” in human hepatocellular carcinoma express a Wnt-induced gene signature associated with poor clinical outcome. Int J Biochem Cell Biol. 2016;81:195–207.
   PubMed Web of Science ®Google Scholar
• Mutlu P, Ural AU, Gündüz U. Differential gene expression analysis related to extracellular matrix components in drug-resistant RPMI-8226 cell line. Biomed Pharmacother. 2012;66(3):228–231.
   PubMed Web of Science ®Google Scholar
• Pasqualini L, Bu H, Puhr M, et al. miR-22 and miR-29a are members of the androgen receptor cistrome modulating LAMC1 and Mcl-1 in prostate cancer. Mol Endocrinol. 2015;29(7):1037–1054.
   PubMedGoogle Scholar
• Fowler A, Thomson D, Giles K, et al. miR-124a is frequently down-regulated in glioblastoma and is involved in migration and invasion. Eur J Cancer. 2011;47(6):953–963.
   PubMed Web of Science ®Google Scholar
• Lietard J, et al. Sp1-mediated transactivation of LamC1 promoter and coordinated expression of laminin-gamma1 and Sp1 in human hepatocellular carcinomas. Am J Pathol. 1997;151(6):1663.
   PubMed Web of Science ®Google Scholar
• Nagendran M, et al. Canonical Wnt signalling regulates epithelial patterning by modulating levels of laminins in zebrafish appendages. Development. 2015;142(2):320–330.
   PubMed Web of Science ®Google Scholar